Spinal Muscular Atrophy Treatment Market Analysis

Treatment Type (Medication, Supportive Care, Spinal Surgery)

Based on treatment type, the medication segment is expected to register a considerable share in the spinal muscular atrophy treatment market. The segment is driven by the widespread use of RNA-based drugs such as Biogen’s Spinraza. Additionally, newer medicines including Evrysdi have provided more convenient and accessible options for patients, further bolstering the medication segment. These drugs are favored as they offer ongoing treatment options compared to one-time, high-cost gene therapies. Moreover, both oral and injectable formulations’ availability, improved accessibility to treatment, permitting different preferences and needs to be met with effective therapy. The continuous need for dosage over time provides a steady demand, making medications a key revenue-generating segment in the market.

Route of Administration (Oral, Parenteral)

Oral segment is likely to dominate spinal muscular atrophy treatment market share of over 62.9% by 2037. Administration of oral SMA treatments at home does not require clinical visits, reducing the load on patients and their families. It is particularly convenient for long-term treatment regimens, as visits to hospitals can be disruptive. This thereby drives the market growth significantly. Furthermore, oral therapies eliminate the need for healthcare resources including nursing support for injections or infusion centers. Cost savings due to this make oral treatments a more appealing option for payers and providers, hence, accelerating their adoption and boosting market growth.

Our in-depth analysis of the market includes the following segments:

Treatment Type	Medication Gene therapy Antisense oligonucleotides Other medications Supportive care Physical therapy Respiratory support Nutritional support Spinal surgery
Type	Werdnig-Hoffmann disease Infant SMA Kugelberg-Welander disease Adult SMA
Route of Administration	Oral Parenteral
End use	Hospitals Specialty clinics Homecare settings Other end-users

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the spinal muscular atrophy treatment market was over USD 8.9 billion.

The market size for the spinal muscular atrophy treatment market is projected to reach USD 73.9 billion by the end of 2037 expanding at a CAGR of 19.3% during the forecast period i.e., between 2025-2037.

The major players in the market are American Physical Therapy Association, Astellas Pharma, Biogen Inc., and others.

In terms of route of administration segment, the oral segment is anticipated to garner the largest market share by 2037 and display lucrative growth opportunities during 2025-2037.

The market in North America is projected to hold the largest market share of 48.9% by the end of 2037 and provide more business opportunities in the future.

Spinal Muscular Atrophy Treatment Market Analysis